Abbott halts global sales of 1st-gen Absorb stents

Abbott (NYSE:ABT) said today it will halt global sales of its 1st-generation Absorb bioresorbable vascular scaffold due to low commercial sales.

In a statement on it’s website, the company said it is discontinuing all sizes of the Absorb bioresorbable vascular scaffold system, effective Sept. 14.

While the current product will be taken off the market, the company said that it will continue development of next-generation devices and monitoring of patients in existing clinical trials.

“We recognize that BRS technologies offer patients the possibility of life without permanent metallic implants, and we will continue to work on a next generation device while monitoring long-term outcomes after stent resorption in current Absorb trials,” the company wrote in a statement on its website.

Abbott said that physicians with existing products are free to implant the devices “if they choose to do so,” but that in the European Union, implants are restricted to centers participating in approved clinical trials.

“We pioneered bioresorbable technology because we believe it offers patients the possibility of life without permanent metallic implants, and we will continue work on a next generation bioresorbable device. We’ll also continue to follow implanted patients in existing Absorb clinical trials to assess long-term outcomes after the scaffold has dissolved. We’re dedicated to developing treatments that help patients with vascular and other heart diseases live their fullest lives,” Abbott wrote.

The post Abbott halts global sales of 1st-gen Absorb stents appeared first on MassDevice.

from MassDevice http://ift.tt/2xVrIEv